February 25, 2016

Fidia to Introduce Hymovis, Next-Generation Hyaluronan

Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain.
February 23, 2016

Bioventus Acquires U.S. Distribution Rights to GELSYN-3 HA Injection

Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee OA.
February 2, 2016

Seikagaku Ceases Development of Enthesopathy Application

Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. 
January 19, 2016

AlloSource Receives Patent for ProChondrix Cartilage Repair Product

AlloSource was awarded U.S. Patent No. 9,186,253, Cartilage mosaic compositions and methods, for its ProChondrix® Cartilage Restoration Matrix allograft product.
January 11, 2016

20,000 Patients Treated with BONESUPPORT’s CERAMENT

BONESUPPORT announced the milestone of >20,000 patients treated worldwide to date with CERAMENT™ injectable drug-eluting bone substitute products.